Within tarantula venom, new hope for safe and novel painkillers found
Screening more than 100 spider toxins, Yale researchers identified a protein from the venom of the Peruvian green velvet tarantula that blunts activity in pain-transmitting neurons. The findings, reported in the March 3 issue of the journal Current Biology, show the new screening method used by the scientists has the potential to search millions of different spider toxins for safe pain-killing drugs and therapies.
Breaking the Egg Barrier: A Sperm Story
Yale Physiology researchers found that sperm hyperactivation is an evolutionary conserved mechanism to penetrate the egg barriers, used as early as in monotreme but diverged to use it as a way of navigation in the female reproductive tract when it become more complicated in placenta mammals.
Elena Gracheva is a finalist of the 2020 Blavatnik National Awards for Young Scientists
Dr. Elena Gracheva, an Associate Professor of Cellular & Molecular Physiology and of Neuroscience, is a 2020 Finalists of the prestigious Blavatnik National Awards for Young Scientists, the world’s largest unrestricted prize for early-career scientists.Source: Elena Gracheva is a finalist of the 2020 Blavatnik National Awards for Young Scientists
The Peruvian Green Velvet Tarantula’s Gift
"Toxineering," a new method developed by investigators at the Kavli Institute for Neuroscience at Yale, may be used to screen millions of spider toxins for safe pain-killing drugs and therapies. With it, Michael Nitabach and his colleagues have identified a protein from the venom of the Peruvian green velvet tarantula that targets an ion channel linked to neuropathic pain.Source: The New York Times